|
1
|
Arafat Hossain M: A comprehensive review
of immune checkpoint inhibitors for cancer treatment. Int
Immunopharmacol. 143:1133652024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J,
Dummer R, et al: Long-term outcomes with nivolumab plus ipilimumab
or nivolumab alone versus ipilimumab in patients with advanced
melanoma. J Clin Oncol. 40:127–137. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Darnell EP, Mooradian MJ, Baruch EN,
Yilmaz M and Reynolds KL: Immune-related adverse events (irAEs):
Diagnosis, management, and clinical pearls. Curr Oncol Rep.
22:392020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kottschade LA: Incidence and management of
immune-related adverse events in patients undergoing treatment with
immune checkpoint inhibitors. Curr Oncol Rep. 20:242018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Elshafie O, Khalil AB, Salman B, Atabani A
and Al-Sayegh H: Immune checkpoint Inhibitors-induced
endocrinopathies: Assessment, management and monitoring in a
comprehensive cancer centre. Endocrinol Diabetes Metab.
7:e005052024. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wright JJ, Powers AC and Johnson DB:
Endocrine toxicities of immune checkpoint inhibitors. Nat Rev
Endocrinol. 17:389–399. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu J, Zhou H, Zhang Y, Fang W, Yang Y,
Huang Y and Zhang L: Reporting of immune checkpoint inhibitor
therapy-associated diabetes, 2015–2019. Diabetes Care. 43:e79–e80.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marchand L, Thivolet A, Dalle S, Chikh K,
Reffet S, Vouillarmet J, Fabien N, Cugnet-Anceau C and Thivolet C:
Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: Description
of pancreatic endocrine and exocrine phenotype. Acta Diabetol.
56:441–448. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Błażowska O, Stróżna K, Dancewicz H,
Zygmunciak P, Zgliczyński W and Mrozikiewicz-Rakowska B: The
Double-edged sword of Immunotherapy-Durvalumab-induced
Polyendocrinopathy-case report. J Clin Med. 13:63222024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goldstraw P, Chansky K, Crowley J,
Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P,
Mitchell A, Bolejack V, et al: The IASLC lung cancer staging
project: Proposals for revision of the TNM stage groupings in the
forthcoming (Eighth) edition of the TNM classification for lung
cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Thompson JA, Schneider BJ, Brahmer J,
Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M,
Dunnington D, et al: NCCN guidelines insights: Management of
Immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc
Netw. 18:230–241. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alrifai T, Ali FS, Saleem S, Ruiz DCM,
Rifai D, Younas S and Qureshi F: Immune checkpoint inhibitor
induced diabetes mellitus treated with insulin and metformin:
Evolution of diabetes management in the era of immunotherapy. Case
Rep Oncol Med. 2019:87813472019.PubMed/NCBI
|
|
14
|
Capitao R, Bello C, Fonseca R and Saraiva
C: New onset diabetes after nivolumab treatment. BMJ Case Rep.
2018:20172209992018. View Article : Google Scholar
|
|
15
|
Chae YK, Chiec L, Mohindra N, Gentzler R,
Patel J and Giles F: A case of Pembrolizumab-induced type-1
diabetes mellitus and discussion of immune checkpoint
inhibitor-induced type 1 diabetes. Cancer Immunol Immunother.
66:25–32. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chaudry A, Chaudry M and Aslam J:
Pembrolizumab: An immunotherapeutic agent causing endocrinopathies.
Cureus. 12:e88362020.PubMed/NCBI
|
|
17
|
Cunha C, Silva E, Vieira AC, Saraiva C and
Duarte S: New onset autoimmune diabetes mellitus and hypothyroidism
secondary to pembrolizumab in a patient with metastatic lung
cancer. Endocrinol Diabetes Metab Case Rep. 2022:21–0123.
2022.PubMed/NCBI
|
|
18
|
de Filette JMK, Pen JJ, Decoster L,
Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO,
Aspeslagh S, Neyns B, et al: Immune checkpoint inhibitors and type
1 diabetes mellitus: A case report and systematic review. Eur J
Endocrinol. 181:363–374. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Delasos L, Bazewicz C, Sliwinska A, Lia NL
and Vredenburgh J: New onset diabetes with ketoacidosis following
nivolumab immunotherapy: A case report and review of literature. J
Oncol Pharm Pract. 27:716–721. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Edahiro R, Ishijima M, Kurebe H, Nishida
K, Uenami T, Kanazu M, Akazawa Y, Yano Y and Mori M: Continued
administration of pembrolizumab for adenocarcinoma of the lung
after the onset of fulminant type 1 diabetes mellitus as an
Immune-related adverse effect: A case report. Thorac Cancer.
10:1276–1279. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Godwin JL, Jaggi S, Sirisena I, Sharda P,
Rao AD, Mehra R and Veloski C: Nivolumab-induced autoimmune
diabetes mellitus presenting as diabetic ketoacidosis in a patient
with metastatic lung cancer. J Immunother Cancer. 5:402017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hatakeyama Y, Ohnishi H, Suda K, Okamura
K, Shimada T and Yoshimura S: Nivolumab-induced Acute-onset type 1
diabetes mellitus as an immune-related adverse event: A case
report. J Oncol Pharm Pract. 25:2023–2026. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang X, Yang M, Wang L, Li L and Zhong X:
Sintilimab induced diabetic ketoacidosis in a patient with small
cell lung cancer: A case report and literature review. Medicine
(Baltimore). 100:e257952021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ishi A, Tanaka I, Iwama S, Sakakibara T,
Mastui T, Kobayashi T, Hase T, Morise M, Sato M, Arima H and
Hashimoto N: Efficacies of programmed cell death 1 ligand 1
blockade in non-small cell lung cancer patients with acquired
resistance to prior programmed cell death 1 inhibitor and
development of diabetic ketoacidosis caused by two different
etiologies: A retrospective case series. Endocr J. 68:613–620.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kedzior SK, Jacknin G, Hudler A, Mueller
SW and Kiser TH: A severe case of diabetic ketoacidosis and
New-onset type 1 diabetes mellitus associated with Anti-glutamic
acid decarboxylase antibodies following immunotherapy with
pembrolizumab. Am J Case Rep. 22:e9317022021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee S, Morgan A, Shah S and Ebeling PR:
Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy.
Endocrinol Diabetes Metab Case Rep. 2018:18–0021. 2018.PubMed/NCBI
|
|
27
|
Li L, Masood A, Bari S, Yavuz S and
Grosbach AB: Autoimmune diabetes and thyroiditis complicating
treatment with nivolumab. Case Rep Oncol. 10:230–234. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li W, Wang H, Chen B, Zhao S, Zhang X, Jia
K, Deng J, He Y and Zhou C: Anti PD-1 monoclonal antibody induced
autoimmune diabetes mellitus: A case report and brief review.
Transl Lung Cancer Res. 9:379–388. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lupi I, Brancatella A, Cosottini M, Viola
N, Lanzolla G, Sgrò D, Dalmazi GD, Latrofa F, Caturegli P and
Marcocci C: Clinical heterogeneity of hypophysitis secondary to
PD-1/PD-L1 blockade: Insights from four cases. Endocrinol Diabetes
Metab Case Rep. 2019:19–0102. 2019.PubMed/NCBI
|
|
30
|
Nishioki T, Kato M, Kataoka S, Miura K,
Nagaoka T and Takahashi K: Atezolizumab-induced fulminant type 1
diabetes mellitus occurring four months after treatment cessation.
Respirol Case Rep. 8:e006852020. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Patel S, Chin V and Greenfield JR:
Durvalumab-induced diabetic ketoacidosis followed by
hypothyroidism. Endocrinol Diabetes Metab Case Rep. 2019:19–0098.
2019.PubMed/NCBI
|
|
32
|
Porntharukchareon T, Tontivuthikul B,
Sintawichai N and Srichomkwun P: Pembrolizumab- and
Ipilimumab-induced diabetic ketoacidosis and isolated
adrenocorticotropic hormone deficiency: A case report. J Med Case
Rep. 14:1712020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ren Y, Zhang L, Wang Y and Zhong D: Immune
checkpoint inhibitors related diabetes mellitus: A report of 2
cases and literature review. Zhongguo Fei Ai Za Zhi. 25:61–65.
2022.(In Chinese). PubMed/NCBI
|
|
34
|
Seo JH, Lim T, Ham A, Kim YA and Lee M:
New-onset type 1 diabetes mellitus as a delayed immune-related
event after discontinuation of nivolumab: A case report. Medicine
(Baltimore). 101:e304562022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sothornwit J, Phunmanee A and
Pongchaiyakul C: Atezolizumab-induced autoimmune diabetes in a
patient with metastatic lung cancer. Front Endocrinol (Lausanne).
10:3522019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tzoulis P, Corbett RW, Ponnampalam S,
Baker E, Heaton D, Doulgeraki T and Stebbing J: Nivolumab-induced
fulminant diabetic ketoacidosis followed by thyroiditis. Endocrinol
Diabetes Metab Case Rep. 2018:18–0111. 2018.PubMed/NCBI
|
|
37
|
Yang J, Wang Y and Tong XM:
Sintilimab-induced autoimmune diabetes: A case report and review of
the literature. World J Clin Cases. 10:1263–1277. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
García-Cortés M, Lucena MI, Pachkoria K,
Borraz Y, Hidalgo R and Andrade RJ: Evaluation of naranjo adverse
drug reactions probability scale in causality assessment of
drug-induced liver injury. Aliment Pharmacol Ther. 27:780–789.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et
al: Durvalumab after chemoradiotherapy in stage III Non-Small-Cell
lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chang LS, Barroso-Sousa R, Tolaney SM,
Hodi FS, Kaiser UB and Min L: Endocrine toxicity of cancer
immunotherapy targeting immune checkpoints. Endocr Rev. 40:17–65.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gardner G and Fraker CA: Natural killer
cells as key mediators in type i diabetes immunopathology. Front
Immunol. 12:7229792021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kani ER, Karaviti E, Karaviti D, Gerontiti
E, Paschou IA, Saltiki K, Stefanaki K, Psaltopoulou T and Paschou
SA: Pathophysiology, diagnosis, and management of immune checkpoint
Inhibitor-induced diabetes mellitus. Endocrine. 87:875–890. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen J, Hou X, Yang Y, Wang C, Zhou J,
Miao J, Gong F, Ge F and Chen W: Immune checkpoint
inhibitors-induced diabetes mellitus (review). Endocrine.
86:451–458. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cho YK and Jung CH: Immune-Checkpoint
Inhibitors-Induced Type 1 diabetes mellitus: From its molecular
mechanisms to clinical practice. Diabetes Metab J. 47:757–766.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Perdigoto AL, Deng S, Du KC, Kuchroo M,
Burkhardt DB, Tong A, Israel G, Robert ME, Weisberg SP,
Kirkiles-Smith N, et al: Immune cells and their inflammatory
mediators modify β cells and cause checkpoint Inhibitor-induced
diabetes. JCI Insight. 7:e1563302022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yoneda S, Imagawa A, Hosokawa Y, Baden MY,
Kimura T, Uno S, Fukui K, Goto K, Uemura M, Eguchi H, et al:
T-Lymphocyte infiltration to islets in the pancreas of a patient
who developed type 1 diabetes after administration of immune
checkpoint inhibitors. Diabetes Care. 42:e116–e118. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu L, Tsang VHM, Sasson SC, Menzies AM,
Carlino MS, Brown DA, Clifton-Bligh R and Gunton JE: Unravelling
checkpoint inhibitor associated autoimmune diabetes: From bench to
bedside. Front Endocrinol (Lausanne). 12:7641382021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kamitani F, Nishioka Y, Koizumi M,
Nakajima H, Kurematsu Y, Okada S, Kubo S, Myojin T, Noda T, Imamura
T and Takahashi Y: Immune checkpoint Inhibitor-related type 1
diabetes incidence, risk, and survival association. J Diabetes
Investig. 16:334–342. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kyriacou A, Melson E, Chen W and
Kempegowda P: Is immune checkpoint Inhibitor-associated diabetes
the same as fulminant type 1 diabetes mellitus? Clin Med (Lond).
20:417–423. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang AL, Wang F, Chang LS, McDonnell ME
and Min L: Coexistence of immune checkpoint inhibitor-induced
autoimmune diabetes and pancreatitis. Front Endocrinol (Lausanne).
12:6205222021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liao D, Liu C, Chen S, Liu F, Li W,
Shangguan D and Shi Y: Recent advances in immune checkpoint
Inhibitor-induced type 1 diabetes mellitus. Int Immunopharmacol.
122:1104142023. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Usui Y, Udagawa H, Matsumoto S, Imai K,
Ohashi K, Ishibashi M, Kirita K, Umemura S, Yoh K, Niho S, et al:
Association of serum Anti-GAD antibody and HLA haplotypes with type
1 diabetes mellitus triggered by nivolumab in patients with
Non-small cell lung cancer. J Thorac Oncol. 12:e41–e43. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Pardini VC, Mourao DM, Nascimento PD,
Vívolo MA, Ferreira SR and Pardini H: Frequency of islet cell
autoantibodies (IA-2 and GAD) in young Brazilian type 1 diabetes
patients. Braz J Med Biol Res. 32:1195–1198. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wei HH, Lai YC, Lin G, Lin CW, Chang YC,
Chang JW, Liou MJ and Chen IW: Distinct changes to pancreatic
volume rather than pancreatic autoantibody positivity: Insights
into immune checkpoint inhibitors induced diabetes mellitus.
Diabetol Metab Syndr. 16:262024. View Article : Google Scholar : PubMed/NCBI
|
